Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial.
AuteursJhaveri KL, Neven P, Casalnuovo ML, Kim SB, Tokunaga E, Aftimos P, Saura C, O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Watanabe J, Lim E, Huang J, Qingyuan Z, Llombart-Cussac A, Huang C, Desai B, Limay Y, Wang XA, Cao S, Bidard FC
Reply to Satapathy et al.'s comment on \"Dual cross-sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014-2022\".
AuteursVan Beckhoven D, Serrien B, Demeester R, Van Praet J, Messiaen P, Darcis G, Henrard S, De Munter P, Libois A, Deblonde J
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
AuteursBhave M, Jhaveri KL, Kaufman PA, Aftimos P, Lombard J, Giridhar KV, Im SA, Ma CX, Lee KT, Kim SB, Sohn J, Li Y, Yuen E, Estrem ST, Nguyen B, Makena MR, Ismail-Khan R, Beeram M
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
AuteursWildiers H, Adam V, O'Reilly S, Van Cauwenberge J, Arahmani A, Arteaga CL, Bedard PL, Bliss J, Boussis P, Brain E, Buyse M, Caballero C, Cameron D, Cardoso F, Carrasco E, Casas A, Chua B, Curigliano G, DeMichele A, Esserman L, Floris G, Goetz MP, Goulioti T, Haibe-Kains B, Hodgdon C, Ignatiadis M, Kok M, Lacombe D, Linderholm B, Loi S, Lord CJ, MacKenzie M, Maues J, Meheus L, Needham J, Neven P, Parsons H, Piccart M, Pusztai L, Razis E, Saji S, Schumacher-Wulf E, Sonke GS, Spanic T, Tannock IF, Tutt A, Urruticoechea A, van 't Veer L, Vaz-Luis I, Werutsky G, Yee D, Zaman K, Desmedt C
